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Abstract
Background: The MitoChip v2.0resequencing array is anarray-based technique allowing for accurate and completesequencing
of the mitochondrial genome. No studies have investigated mitochondrial mutation in salivary gland adenoid cystic carcinomas.
Methodology: The entire mitochondrial genome of 22 salivary gland adenoid cystic carcinomas (ACC) of salivary glands and
matched leukocyte DNA was sequenced to determine the frequency and distribution of mitochondrial mutations in ACC
tumors.
Principal Findings: Seventeen of 22 ACCs (77%) carried mitochondrial mutations, ranging in number from 1 to 37
mutations. A disproportionate number of mutations occurred in the D-loop. Twelve of 17 tumors (70.6%) carried mutations
resulting in amino acid changes of translated proteins. Nine of 17 tumors (52.9%) with a mutation carried an amino acid
changing mutation in the nicotinamide adenine dinucleotide dehydrogenase (NADH) complex.
Conclusions/Significance: Mitochondrial mutation is frequent in salivary ACCs. The high incidence of amino acid changing
mutations implicates alterations in aerobic respiration in ACC carcinogenesis. D-loop mutations are of unclear significance,
but may be associated with alterations in transcription or replication.
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Introduction
Adenoid cystic carcinoma (ACC) of the salivary gland is a rare
malignancy, comprising 1% of all head and neck tumors, 10% of
all salivary gland masses, and 22% of all salivary gland
malignancies. Surgical therapy with adjuvant radiation is the
mainstay of treatment. The clinical behavior of ACC is atypical
with an almost 40% incidence of distant metastases despite
adequate local control with surgery and external beam irradiation
[1]. Other atypical clinical features of ACC include a variable
survival in patients with metastatic disease in a site dependent
fashion. Patients with isolated pulmonary metastases have a much
longer survival relative to patients with bone involvement [2].
Many types of combination chemotherapy and molecular
therapy have been investigated for use in ACC. Limited response
has been demonstrated in any regimen which has been employed
in a clinical trial to this point [3]. There are a number of newer
trials in progress, but there have been no major breakthroughs in
chemotherapy for ACC.
The basis of these disappointing results is a lack of understand-
ing of the basic biologic mechanisms involved in ACC. Several
preliminary studies have investigated DNA alterations of known
proto-oncogenes and tumor suppressor genes in ACC [4–12].
However, a clear picture of the molecular underpinnings of this
malignancy is not apparent. Cytogenetic studies of ACC have
demonstrated a pattern of chromosomal alterations that are not
consistent with known solid tumor types, suggesting that there may
be different mechanisms involved in its carcinogenesis [13].
Recent studies of other solid tumors have investigated the
incidence and role of somatic mitochondrial mutations and their
implications for carcinogenesis [14–24]. The mitochondrial
genome is a 16.6.kb double stranded circular DNA containing
no introns, including 13 genes that encode proteins that are
involved in aerobic respiration, 22 transfer RNAs, and 2 ribosomal
RNAs. The mitochondrial genome contains limited DNA repair
mechanisms and is susceptible to DNA damage acquired from
both reactive oxygen species (ROS) generated by cellular
metabolism and from extrinsic carcinogens including tobacco
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potentially cause generation of additional ROS due to impairment
of oxidative phosphorylation, facilitating DNA damage to the
nuclear or mitochondrial genome as well as dysregulation of
apoptosis and other cellular processes [25].
The advent of sensitive oligonucleotide sequencing arrays has
led to novel possibilities for molecular detection of cancer. Studies
of a previous version of the MitoChip have proven its fidelity and
reproducibility, and demonstrated the promise in application of
mitochondrial sequencing in detection of tumor specific mito-
chondrial alterations [26]. Recently, a study by our group, utilizing
a high throughput mitochondrial sequencing array for the entire
mitochondrial genome has demonstrated a 49% of incidence of
mitochondrial mutation in head and neck squamous cell
carcinoma in another limited cohort [27]. A related study using
the MitoChip identified mitochondrial mutations in premalignant
gastrointestinal tract lesions [28].
No studies thus far have investigated mitochondrial DNA
mutations in adenoid cystic carcinoma. A single report has
demonstrated scattered mitochondria and a paucity of endoplas-
mic reticulum in adenoid cystic carcinoma derived from minor
salivary glands [29], though this was only a histologic analysis. Due
to the lack of understanding of the molecular mechanisms in
carcinogenesis of ACC and the potential therapeutic implications
of identification of novel therapeutic targets, this study was
designed to investigate the incidence and distribution of mito-
chondrial mutation in ACC. We utilize a whole mitochondria
sequencing array, the MitoChip v2.0 [27] to characterize the
mutations that are present throughout the mitochondrial genome
in 22 adenoid cystic carcinomas of the salivary glands in order to
determine the prevalence and distribution of mitochondrial
mutations in this disease.
Materials and Methods
Human Mitochondrial v2.0 Oligonucleotide Microarray
The MitoChip v2.0 was obtained from Affymetrix (commer-
cially available GeneChip Human Mitochondrial Resequencing
Array 2.0; Santa Clara, CA). Sequences comprising both strands
of the entire human mitochondrial genome were synthesized as
overlapping 25-mers on high-density oligonucleotide arrays with
868-mm features. To query any given site from the human
mitochondrial reference sequence, four features are tiled on the
MitoChip. The four features differ only by the 13th base, which
consists of each of the four possible nucleotides.
DNA Sample Source and Preparation
Tumor samples and leukocyte DNA were obtained from resected
specimens of 22 patients with adenoid cystic carcinoma who
undergone enrollment in institutional review board had approved
protocols at Johns Hopkins Hospital and the University of Texas
M.D.AndersonCancerCenterafterinformedconsentwasobtained.
At the Johns Hopkins Hospital, tumors were collected under IRB
#92-07-21-01, and at the M.D. Anderson Cancer Center, tumors
were collected under IRB #Lab92-018. The research was
performed at Johns Hopkins under the IRB #NA_00001336.
Written informed consent was obtained from all those patients.
Tumor specimens were snap frozen in liquid nitrogen and stored at
280 degrees Celsius. Samples were microdissected on a cryostat so
that the tumor samples contained greater than 70% neoplastic cells.
DNA from tumor sections was digested with 1% sodium dodecyl
sulfate/proteinase K, extracted by phenol-chloroform, and ethanol
precipitated. Control DNAs from peripheral lymphocytes were
processed in the same manner as described previously [30].
Mitochondrial mutation status in these tumors were identified by
sequencing of tumors and matched leukocyte DNA samples using
the MitoChip v 2.0 mitochondrial resequencing array (Affymetrix;
Santa Clara, CA) as previously described [27] by comparison of
tumor sequence with matched leukocyte sequence, to identify true
mutations rather than polymorphisms.
Mitochip Preparation
The entire mitochondrial DNA sequence was amplified in three
overlapping polymerase chain reactions using 50 ng of genomic
DNA each [26]. The reagents, conditions, and purification
procedures were accomplished as described previously [27]. These
three sets of PCR primers were F1: 59-ATA GGG GTC CCT
TGA CCA CCA TCC TCC GT-39 and R1: 59-GAG CTG TGC
CTA GGA CTC CAG CTC ATG CGC CG-39, F2: 59-CCG
ACC GTT GAC TAT TCT CTA CAA ACC AC-39 and R2: 59-
GAT CAG GAG AAC GTG GTT ACT AGC ACA GAG AG-
39, F3: 59-CAT TCT CAT AAT CGC CCA CGG GCT TAC
ATC C-39 and R3: 59-GTT CGC CTG TAA TAT TGA ACG
TAG GTG CC-39. Amplification was accomplished in 50-ml PCR
reaction performed in thin-walled polypropylene plates using the
high-fidelity TaKaRa LA Taq (TaKaRa Mirus Bio, Madison,
WI). The PCR conditions are 94uC for 2 min, 30 cycles of 94uC
for 15 sec, 68uC for 7 min, and then an extension step at 68uC for
12 min followed by holding at 4uC. As a control for PCR
amplification and subsequent hybridization, a 7.5-kb plasmid
DNA (Tag IQ-EX template) was amplified concomitantly with the
test samples, using forward and reverse primers included in the
CustomSeq control kit (Affymetrix, Inc.). The specificity of the
reactions was confirmed by agarose gel electrophoresis. The PCR
products were purified using QIAQuick PCR Clean up kit
(Qiagen, Inc., Valencia, CA), and the resultant purified DNA was
resuspended in 30 to 40 ml of EB buffer (Affymetrix, Inc.). The
concentration of each purified PCR product was determined by
NanoDrop (Thermo scientific). PCR products from three reactions
were mixed in equal molar concentrations. The pooling, DNA
fragmentation, labeling, and chip hybridization were performed
according to Affymetrix CustomSeq Resequencing protocol
instructions.
The pooled 35 ul of DNA fragments were then digested with
DNase I (0.2 U of DNase I/mg DNA) for 15 minutes in a 50-ml
reaction (Affymetrix, Cat. 900447). Samples were then incubated
at 95uC for 15 minutes to inactivate DNase I. Fragmented DNA
was labeled by adding 2.0 ml of GeneChip DNA labeling reagent
and 3.4 mlo f3 0U / ml terminal deoxynucleotidyl transferase (both
from Affymetrix). The labeling conditions were 37uC 90 min and
95uC 15 min. Prehybridization, hybridization, washing, and
scanning of the MitoChip were performed as described in the
Affymetrix CustomSeq Resequencing protocol. The prehybridiza-
tions were performed for 15 minutes in 80-ml (for v2.0 chips)
solution containing 3 mol/L tetramethylammonium chloride,
0.1% Tween 20, and 10 mmol/L Tris, pH 7.8. The GeneChips
for human mitochondrial resequencing array 2.0 (Affymetrix, Cat.
900886) were hybridized for 16 hours at 48uC with 60 rpm
rotation in a hybridization solution containing 3 mol/L tetra-
methylammonium chloride, 100 mg/ml herring sperm DNA,
500 mg/ml bovine serum albumin, 10 mmol/L Tris, pH 7.8,
0.01% Tween 20, and 200 pmol/L control oligo. The chips were
then washed on the Affymetrix fluidics station using the
preprogrammed CustomSeq Resequencing wash protocols.
Automated Batch Analysis of Microarray Data
Analysis of microarray data for the v2.0 MitoChips was done
using GeneChipH Sequence Analysis Software (GSEQ) v 4.0
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upon the ABACUS algorithm [31] to assign base calls to each
position which meets quality criteria in the mitochondrial genome.
The original ABACUS algorithm has been successfully applied for
high-throughput variation detection in humans as well as for
detection of mitochondrial sequence variations in human embry-
onic stem cells and head and neck cancers [27,32].GSEQ software
was used per manufacturer’s instructions, with Genome model set
to ‘‘diploid’’ and Quality Score Threshold set to ‘‘3’’ to maximize
base call percentage and fidelity.
Results
Demographics
Tumor samples were derived from 22 patients who underwent
resection of primary or locally recurrent lesions, and one sample
was derived from nodal disease at the time of initial resection of
ACC. Samples were collected at Johns Hopkins Hospital and
M.D. Anderson Cancer Center between 1992 and 2005 in the
operating room and immediately snap frozen with liquid nitrogen.
Tissue sources utilized to acquire tumor DNA in this study and
other demographic information is recorded in Table 1. Mean age
of the patients was 55 years (Range 18–74). Mean follow-up time
was 68.1 months (Range 7–190 months). Twenty-one of 22
patients (95.5%) received adjuvant radiation, and 14/22 patients
(64%) developed recurrence after resection. One patient (Patient 5)
presented with locally recurrent and metastatic disease after
resection at another institution. Of the patients who recurred after
resection at our institutions, median time to recurrence was 24
months (Range 1–93 months).
D-loop and NADH Complex Are Mutated in the Majority
of Salivary Gland Adenoid Cystic Carcinomas
In total, 727,936 bases were sequenced from 44 samples
comprised of DNA derived from 22 tumors and matched
peripheral blood leukocytes to provide germ line mitochondrial
sequence data. The median call rate of sequencing for each sample
was 98.05% (Range 93.5%–99.9%). Mitochondrial mutations,
defined as sequence differences between tumors and germ line
DNA were identified in 17/22 (77%) samples tested. One hundred
forty two mitochondrial mutations were identified (Table S1,
range 1–37 mutations/tumor). D-loop mutations were identified in
11/22 (50%) tumors (Range 1–13 mutations/tumor), and 51
mutations were identified in NADH complex genes.
Thirty eight non-synonymous mutations were present among
12/22 (54.5%) tumors (Range 1–12 mutations) (Table 2). Twenty-
two of 38 (57.8%) of non-synonymous mutations occurred in
NADH complex genes, with 9/12 (75%) tumors carrying amino
Table 1. Demographic and clinical patient data.
Staging _ _ Size Followup Lung Total D-loop AA NADH
Patient Sex Age Ethnicity
1 Location T N M (cm) X-RT DFI
2 (Month) Met
3 LR
4 Mut. Mut. Mut. Complex
1 M 49 C Maxilla 1 0 x - Y - 161 22 11 00
2 F 61 AA BOT
5 20 x - Y - 1 5 5 22 71 54
3 F 18 A Maxilla - - 1 - Y 93 167 ++ 00 00
4 F 43 C BOT 4 2 x 6.5 Y - 27 22 20 21
5 M 31 A Parotid - - 1 - Y 190 190 ++ 37 6 12 5
6 F 68 C EAC
6 1 0 0 0.5 Y - 48 22 29 13 4 3
7 M 51 AA Submandibular 2 0 0 - N 18 65 ++ 11 1 1 0
8 F 73 C Maxilla 3 0 x 4.6 Y - 18 22 00 00
9 F 73 H Parotid 2 0 x 3 Y 47 55 + 2 30 20
10 F 74 C Parotid 2 0 x 3 Y 44 100 + 2 31 00
11 M 30 C Parotid 4 2 1 15 Y 1 13 + 2 10 11
12 M 52 C Parotid 2 0 x 3.7 Y 9 17 + 2 20 10
13 F 74 C Parotid 4 0 x 7 Y - 57 22 21 00
14 M 63 H Parotid 2 0 x 4 Y 6 7 2 + 31 11
15 M 48 C Parotid 3 0 x 5.5 Y 92 112 + 2 31 11
16 M 73 C Parotid 3 0 x 6 Y 24 40 + 2 00 00
17 M 69 AA BOT 2 0 x 2.5 Y 22 30 ++ 10 00
18 F 34 C Maxilla 2 0 x 3.5 Y 11 27 + 2 00 00
19 F 67 H BOT 3 0 x 4 Y - 42 22 30 00
20 M 51 C Submandibular 2 0 x 3.2 Y - 42 22 61 41
21 F 73 C Submandibular 2 0 x 2.5 Y 26 47 + 2 28 6 3 1
22 M 44 AA BOT 3 0 x 6 Y 72 79 + 2 00 00
1C: Caucasian, AA: African American, A: Asian, H: Hispanic.
2DFI: disease free interval (Month).
3Lung metastasis.
4LR: local recurrence.
5BOT: Base of Tongue.
6EAC: External Auditory Canal.
doi:10.1371/journal.pone.0008493.t001
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NADH complex genes. Three of these tumors carried multiple
mutations in NADH complex genes.
Mutations Appear to be Distributed Nonrandomly
Throughout the Mitochondrial Genome
Most mitochondrial mutations are spread throughout the genome
with frequencies roughly proportional to the size of the gene in which
they are found relative to the size of the mitochondrial genome
(Table 3). However, the incidence of mutations in the D-loop is
significantly higher than expected for a random distribution of
mutations based upon the size of the region alone (23.2% of mutations
vs 6.8% of total size of genome, p value,0.01, Chi Square Test).
Utilizing bivariate analysis, no other statistically significant
association was identified between the number, distribution, or
nature (synonymous or non-synonymous) of mitochondrial
mutations and metastases, recurrence, ethnicity, initial stage, or
location of tumors.
Table 2. Non-synonymous somatic mitochondrial DNA and amino acid alterations.
mtDNA Mut. Amino acid Mut.
Patient Position
1 Gene Reference
2 Leukocyte Tumor Leukocyte Tumor
2 9450 COIII G G T G W
2 10371 ND3 G G A E K
2 10602 ND4L A A G T A
2 10848 ND4 A A G H R
2 12650 ND5 T T C L P
4 9097 ATPase6 A A G I V
4 10967 ND4 A A G T A
5 3788 ND1 A A G N S
5 3789 ND1 C C G N K
5 5302 ND2 T T C I T
5 5910 COI G G A A T
5 6391 COI A A C N T
5 9053 ATPase6 G G A S N
5 9055 ATPase6 G A G T A
5 10398 ND3 A G A A T
5 10491 ND4L A A G N Y
5 10609 ND4L T T C M T
5 12406 ND5 G G A V I
5 13928 ND5 G G C S T
6 4216 ND1 T C T H Y
6 10398 ND3 A G A A T
6 12612 ND5 A G A E V
6 15257 Cytb G A G N D
7 6112 COI T T C V A
7 14577 ND6 T T C I N
9 9080 ATPase6 A A C N T
9 14786 Cytb A A T I F
11 11202 ND4 A A C Y S
12 15837 Cytb T T G I S
14 3614 ND1 T T G L R
15 5074 ND2 T T C I T
20 7641 COII A A G E G
20 8249 COII G G A G STOP
20 10576 ND4L T T C M T
20 14758 Cytb A A G M V
21 8075 COII G G A A T
21 9055 ATP6 G G A A T
21 10398 ND3 A A G T A
1,2based on GenBank Homo sapiens mitochondrial genome, NC_012920.
doi:10.1371/journal.pone.0008493.t002
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In this study we have applied a high throughput approach to
sequencing the entire mitochondrial genome to salivary gland
ACC samples and compared these sequences to matched germ
line samples in order to determine the incidence and nature of
mitochondrial mutations in this disease. This report represents the
first investigation of the frequency of mitochondrial mutation in
this disease. Additionally, we have identified a region of the
mitochondrial genome, the D-loop which is selectively mutated in
ACC at a rate that is much higher than the remainder of the
genome. The majority of tumors with amino acid changing
mutations demonstrated a mutation in the ND complex.
The high incidence of amino acid changing mutations in the ND
complexandobservationofapropensityforaccumulationofmultiple
mutations once mitochondrial damage is initiated is consistent with a
role of mitochondrial mutation as a potentiator of DNA damage in
ACC. Previous studies from our group have shown ND complex
mutations, particularly, the ND2 mutation, is accompanied by
increased ROS generation and hypoxia inducible factor-a (HIF-1a)
stabilization and anchorage independent growth [33]. Another study
has implicated ND6 mutation with dysregulation of response to
hypoxia in glioma cells [34]. Sequential mutation of the ND complex
in ACC may result in a spiraling cycle of increased ROS production
and dysfunction of the aerobic glycolytic mechanism with subse-
quently increased propensity for further mutation and dysfunction
resulting in a competitive growth advantage for tumor cells.
Mitochondrial mutations in several gene complexes have been
shown to contribute to tumorigenicity through ROS generation in
several tumor types [33,35,36]. A recent study has demonstrated
conference of metastatic potential by ND1 complex mutation
through ROS generation in a tumor specific fashion [37]. This
parallels the finding of worsening prognosis with increased
mitochondrial mutation cervical cancer [38]. While we did not
detect an association between mitochondrial mutation and the
clinical behavior of ACC, larger studies may need to be performed
to adequately address this question.
We made a comparison of our reported somatic mitochondrial
nonsynonymous mutations to the mitochondrial genome database
[39]. Several non-synonymous mutations that were reported
previously might have functional correlations with human disease.
In our study, we found two out of 22 cases with G10398A
mutation in ND3, while one patient had the reverse alteration
detected (A10398G). G10398A had been associated with invasive
breast cancer and esophageal cancer in African American
individuals[40–42]. However, there is also conflicting evidence
to suggest that this is not the case[43]. Interesting, the reverse
finding (A10398G mutation) was detected in thyroid carcinoma as
well [23]. Another mutation, T4216C found in ND1 in patient
#6, was suggested to increase risk of insulin-resistance and type 2
diabetes [44]. Evidence also supports its association with Leber
hereditary optic neuropathy [45]. T14577C mutation in ND6 was
also implicated as the pathogenic mutation for maternally
inherited type 2 diabetes [46].
Table 3. Proportion of mitochondrial DNA and amino acid changes to gene size.
Gene Size (bp) % of Genome # of mtDNA Mut. % of mtDNA Mut. # of AA Mut.
12S Ribosomal RNA 953 5.8 3 2.1 -
16S Ribosomal RNA 1557 9.4 10 7.0 -
ATPase6 680 4.1 7 4.9 5
ATPase8 206 1.2 1 0.7 0
COI 1541 9.3 11 7.7 3
COII 701 4.2 7 4.9 3
COIII 783 4.7 3 2.1 1
Cytb 1140 6.9 8 5.6 4
D-Loop 1121 6.8 33 23.2 -
ND1 955 5.8 8 5.6 4
ND2 1041 6.3 5 3.5 2
ND3 345 2.1 6 4.2 4
ND4 1377 8.3 13 9.2 3
ND4L 296 1.8 7 4.9 4
ND5 1811 10.9 10 7.0 4
ND6 524 3.2 2 1.4 1
tRNA arginine 64 0.4 1 0.7 -
tRNA isoleucine 68 0.4 2 1.4 -
tRNA serine 1 70 0.4 1 0.7 -
tRNA alanine 68 0.4 1 0.7 -
tRNA asparagine 72 0.4 1 0.7 -
tRNA methionine 67 0.4 1 0.7 -
tRNA leucine 2 70 0.4 1 0.7 -
Total 142 100.0
doi:10.1371/journal.pone.0008493.t003
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our ACC cohort as reported in other tumor types raises the
possibility that these mutations in particular might play a role in
positively selecting for these cancer cells beyond random mutation.
Zhidkov et al [47] suggest that these alterations form a pattern of
mutation that can be traced to ancient phylogeny. This finding
further implicates these mutations as being functionally relevant as
they have persisted through evolutionary pressures.
The mitochondrial D-loop is an approximately 1kB region of
the mitochondrial genome which contains cis-acting elements
involved in regulation of transcription and replication of the
mitochondrial genome [48]. The exact contribution of the D-loop
to carcinogenesis is poorly understood, however, mutation of the
D-loop has been associated with alterations in mitochondrial copy
number in a variety of solid tumors [49–51]. Our findings of
disproportionate degree of mutation of the D-loop are consistent
with previous studies showing alterations in regulation of
mitochondrial transcription and replication may contribute to
carcinogenesis in ACC.
Identification of mitochondrial mutations in ACC has impor-
tant implications for disease detection and therapy. The relative
chemoresistance of this tumor type makes identification of novel
therapeutic targets imperative to improvement of treatment for
this disease. Amino acid changing mutations of the complexes
regulating oxidative phosphorylation carry immunologic implica-
tions as well as functional implications [52]. Further studies are
warranted, but it seems feasible that alterations in immunogenicity
are inherent with the mutations which have been identified. This
may provide additional, disease specific, targets for immunother-
apy in ACC.
Application of the quantitative nature of the techniques
employed in this study may be useful for detection of tumor
specific mitochondrial mutations as an adjunctive study in margin
analysis. Previous studies by our group have shown that the
MitoChip can be successfully employed to detect tumor specific
mitochondrial mutations in a background of normal DNA [33].
The high incidence of local and regional recurrence despite
complete resection as assessed by conventional pathologic
assessment demonstrates the need for development of molecular
techniques to evaluate margins in this disease.
One of the limitations of this study is that we have a relatively
small cohort of ACC due to the rare nature of this malignancy,
with approximately 600 new cases diagnosed each year in the US.
Future studies with larger sample size would be beneficial to better
understand the relationship of somatic mitochondrial mutations
and ACC.
In this study we have employed a genome wide sequencing
technique to identify mitochondrial mutations in adenoid cystic
carcinoma. We have reported a high incidence of mitochondrial
mutation in ACC, a novel finding. Further investigation is
warranted as to the functional implications of these mutations in
carcinogenesis. However, these findings and the technique utilized
to identify them has significant potential for novel detection
methods and therapy in this disease.
Supporting Information
Table S1 Summary of somatic mitochondrial mutations in ACC
Found at: doi:10.1371/journal.pone.0008493.s001 (0.04 MB
XLS)
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